Publicaciones en colaboración con investigadores/as de University of Innsbruck (18)

2024

  1. Relapse in clinically stable adult patients with schizophrenia or schizoaffective disorder: evidence-based criteria derived by equipercentile linking and diagnostic test accuracy meta-analysis

    The Lancet Psychiatry, Vol. 11, Núm. 1, pp. 36-46

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

2022

  1. Scalability of the Positive and Negative Syndrome Scale in first-episode schizophrenia assessed by Rasch models

    Acta Psychiatrica Scandinavica, Vol. 146, Núm. 1, pp. 21-35

  2. The transition from adolescence to adulthood in patients with schizophrenia: Challenges, opportunities and recommendations

    European Neuropsychopharmacology, Vol. 59, pp. 45-55

2021

  1. Baseline Levels of C-Reactive Protein and Proinflammatory Cytokines Are Not Associated with Early Response to Amisulpride in Patients with First Episode Psychosis: The OPTiMiSE Cohort Study

    Schizophrenia Bulletin Open, Vol. 2, Núm. 1

  2. Symptom Remission and Brain Cortical Networks at First Clinical Presentation of Psychosis: The OPTiMiSE Study

    Schizophrenia bulletin, Vol. 47, Núm. 2, pp. 444-455

2019

  1. Correction: Stratification and prediction of remission in first-episode psychosis patients: the OPTiMiSE cohort study (Translational Psychiatry, (2019), 9, 1, (20), 10.1038/s41398-018-0366-5)

    Translational Psychiatry

  2. Stratification and prediction of remission in first-episode psychosis patients: the OPTiMiSE cohort study

    Translational Psychiatry, Vol. 9, Núm. 1

2018

  1. Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study

    The Lancet Psychiatry, Vol. 5, Núm. 10, pp. 797-807

2017

  1. Bitopertin in Negative Symptoms of Schizophrenia—Results From the Phase III FlashLyte and DayLyte Studies

    Biological Psychiatry, Vol. 82, Núm. 1, pp. 8-16

2015

  1. Magnetic resonance imaging and the prediction of outcome in first-episode schizophrenia: A review of current evidence and directions for future research

    Schizophrenia Bulletin, Vol. 41, Núm. 3, pp. 574-583

  2. Modeling determinants of medication attitudes and poor adherence in early nonaffective psychosis: Implications for intervention

    Schizophrenia Bulletin, Vol. 41, Núm. 3, pp. 584-596

  3. The optimization of treatment and management of schizophrenia in Europe (OPTiMiSE) trial: Rationale for its methodology and a review of the effectiveness of switching antipsychotics

    Schizophrenia Bulletin, Vol. 41, Núm. 3, pp. 549-558

  4. The promise of biological markers for treatment response in first-episode psychosis: A systematic review

    Schizophrenia Bulletin, Vol. 41, Núm. 3, pp. 559-573

2014

  1. Efficacy and safety of adjunctive bitopertin (10 and 20mg) versus placebo in subjects with persistent predominant negative symptoms of schizophrenia treated with antipsychotics - Results from the Phase III FlashLyte Study

    Schizophrenia Research, Vol. 158, Núm. 1-3

  2. Schizophrenia-Time to commit to policy change

    Schizophrenia Bulletin, Vol. 40, Núm. SUPPL. 3

2013

  1. Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia

    Schizophrenia Research, Vol. 150, Núm. 2-3, pp. 328-333

2009

  1. Advantages and disadvantages of combination treatment with antipsychotics. ECNP Consensus Meeting, March 2008, Nice

    European Neuropsychopharmacology, Vol. 19, Núm. 7, pp. 520-532